Abstract

Myostatin is a negative regulator of muscle mass. Important advances in our understanding of thecomplex biology of this factor have revealed the therapeutic potential of antagonizing the myostatin pathway. Herewe present the rationale for evaluating anti-myostatin therapies in human muscle-wasting disorders.

Keywords: Myostatin, Muscle, Adipose tissue, Rhabdomyosarcoma, Myostatin antagonism, Myostatin processing and signaling, therapeutic approaches